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ABSTRACT
Predicting age-specific metabolism is important for evaluating age-
related drug and chemical sensitivity. Multiple cytochrome P450s
and carboxylesterase enzymes are responsible for human pyre-
throid metabolism. Complete ontogeny data for each enzyme are
needed to support in vitro to in vivo extrapolation (IVIVE). This study
was designed to determine age-dependent human hepatic CYP2C8
expression, for which only limited ontogeny data are available, and
to further define CYP1A2 ontogeny. CYP2C8 and 1A2 protein levels
were measured by quantitative Western blotting using liver micro-
somal samples prepared from 222 subjects with ages ranging from
8 weeks gestation to 18 years after birth. The median CYP2C8
expression was significantly greater among samples from subjects
older than 35 postnatal days (n = 122) compared with fetal samples
and those from very young infants (fetal to 35 days postnatal, n = 100)
(0.00 vs. 13.38 pmol/mgmicrosomal protein; p < 0.0001). In contrast,
the median CYP1A2 expression was significantly greater after
15 months postnatal age (n = 55) than in fetal and younger postnatal
samples (fetal to 15 months postnatal, n = 167) (0.0167 vs. 2.354
pmol/mgmicrosomal protein; p < 0.0001). CYP2C8, but not CYP1A2,
protein levels significantly correlatedwith those of CYP2C9, CYP2C19,
and CYP3A4 (p < 0.001), consistent with CYP2C8 and CYP1A2
ontogeny probably being controlled by different mechanisms. This
study provides key data for the physiologically based pharmacokinetic
model–based prediction of age-dependent pyrethroid metabolism,
which will be used for IVIVE to support pyrethroid risk assessment
for early life stages.
Introduction
Substantial changes occur in physiologic and biochemical processes
during development and growth (Clewell et al., 2002). Such changes can
substantially affect chemical disposition in the growing body, resulting
in age-related differences in therapeutic efficacy or toxicity (Hines,
2008; Miyagi et al., 2012). Developmental changes in the expression of
xenobiotic-metabolizing enzyme systems must be taken into account to
better understand age-dependent sensitivity to chemicals, as metabolism
can be amajor determinant of compound disposition and/or toxicity. The
increased synthetic pyrethroid deltamethrin neurotoxicity and lethality
observed in young rats is a good example of age-related sensitivity due
to immature metabolizing enzyme systems overwhelmed by the high
chemical doses typically applied in rodent toxicity studies (Sheets et al.,
1994; Anand et al., 2006). Juvenile susceptibility to pyrethroids in
animal studies led to the present concern over potential differential
sensitivity of pyrethroid insecticides between juveniles and adults due to
their predominant exposure to humans in residential settings (Heudorf
and Angerer, 2001; Schettgen et al., 2002).
Hepatic cytochrome P450 (P450) and carboxylesterases (CES) are
important enzymes involved in pyrethroid metabolism and clearance in
both rats and humans (Anand et al., 2006; Godin et al., 2006, 2007; Ross
et al., 2006; Crow et al., 2007; Scollon et al., 2009). The P450 enzymes are
capable of catalyzing oxidative transformation of the pyrethroids (Scollon
et al., 2009), and the CES enzymes exhibit hydrolysis of some, but not all,
pyrethroids in humans (Ross et al., 2006). It is noted that significant species
differences exist in the relative importance of various P450 and CES
enzymes responsible for pyrethroid metabolism and detoxification. In the
rat, the oxidative reactions of the pyrethroids are dominated by CYP1A1,
1A2, 2C6, 2C11, and 3A1, whereas CYP2C8, 2C19, and 3A4 are the
predominant contributors in humans (Godin et al., 2007; Scollon et al.,
2009). In contrast to rats, human CES1 is important for the hydrolysis of
several pyrethroids (Ross et al., 2006). In addition, serum esterases
demonstrate significant activity in rats, but not in humans (Crow et al.,
2007). Moreover, metabolic competency for some pyrethroids develops
late in rats, as indicated by the age-dependent increase in hepatic intrinsic
clearance of deltamethrin in rats (Anand et al., 2006; Kim et al., 2010).
However, because of clear species differences in the contribution of each
P450 and/or CES enzyme tometabolism of a given pyrethroid, it is difficult
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to generalize age dependency in metabolism in humans from rodent data.
Thus, information on the developmental changes of the human P450 and
CES enzymes involved in pyrethroidmetabolisms is critical to examine the
juvenile sensitivity in humans.
The developmental trajectories of human CYP2C8, CYP2C19,
CYP3A4, CES1, and CES2, the major metabolic contributors to pyrethroid
metabolisms, have been well characterized (Stevens et al., 2003;
Koukouritaki et al., 2004; Hines, 2008, 2012; Scollon et al., 2009; Hines
et al., 2016). However, limited knowledge is available on the ontogeny of
human CYP2C8 despite its potential importance in pyrethroid metabolism
(Scollon et al., 2009) and its abundance in the human liver (Yeo et al., 2004;
Achour et al., 2014). Johnson et al. (2006) demonstrated that the develop-
ment of CYP2C8 with age was best described by a hyperbolic model, but
they had incomplete data on early ages (0–2 years only). Naraharisetti et al.
(2010) characterized hepatic CYP2C8protein expression in individualswith
different CYP2C8 genotypes, but their study failed to include early life ages
(median age 46 years, range 7–70 years). In addition to CYP2C8, human
CYP1A2 is expected to demonstrate pyrethroid metabolic activity, and the
available CYP1A2 data are insufficient for in vitro to in vivo extrapolation
(IVIVE) (Scollon et al., 2009).
The objective of this study was to determine age-dependent
expression levels of human hepatic CYP2C8 and CYP1A2 to fill the
current data gap of enzyme ontogeny information, using a human liver
tissue bank (Koukouritaki et al., 2004). A total of 222 human liver
microsome samples were examined, with ages ranging from 8 weeks
gestation to 18 years after birth. Our findings support IVIVEmodeling to
predict pyrethroid metabolism for different ages by incorporating
enzyme ontogeny and expressed enzyme kinetic data. Similar ap-
proaches can be applied to predict age-appropriate metabolism param-
eters for other environmental compounds.
Materials and Methods
Human Liver Tissue Bank. The microsomal samples consisting of
222 cryopreserved microsomal liver tissue fractions obtained from donors
ranging in age from 8 weeks gestation to 18 years after birth were obtained from
the Brain and Tissue Bank for Developmental Disorders, University of Maryland
(Baltimore, MD); University of Miami (Coral Gables, FL; National Institute of
Child Health and Human Development contract HD-83284); and the Central
Laboratory for Human Embryology at the University of Washington (Seattle,
WA; National Institute of Child Health and Human Development contract
HD-00836). Liver microsomal fractions were prepared by differential centrifu-
gation as described by Koukouritaki et al. (2004) and stored at 80C until used for
Western blotting analysis. The same samples have been used previously to
characterize the developmental expression pattern of other microsomal and
cytosolic proteins. Samples from individuals with disease processes that would
have potentially involved liver pathology were excluded, and more information
on clinical exclusion criteria is described in the Supplemental Methods. The
demographics of the donors are presented in Table 1. The median agewas 56 days
postnatal with 61% male and 34% female donors. The collection and described
use of these tissue samples was considered exempt by the Children’s Hospital and
Health System of Wisconsin Institutional Review Board.
Other Materials. Primary polyclonal antibody raised in rabbit against human
CYP2C8 was obtained from GeneTex (Irvine, CA) (cat. no. GTX113666, lot
number 40464). Primary monoclonal antibody raised in mouse against human
CYP1A2 was obtained from GeneTex (cat. no. GTX84639, lot number
821403197). Purified secondary antibody against CYP2C8 (cat. no. 926-68021,
lot number C40415-04) and purified secondary antibody against CYP1A2 (cat.
no. 926-32210, lot number C40528-02) were obtained from LI-COR Biosciences
(Lincoln, NE). Specificity of the primary antibodies was verified by evaluating
cross-reactivity of the CYP2C8 and 1A2 primary antibodies against the same
loading amounts of other cytochrome P450s, including CYP1A1, 3A4, 3A5, 1B1,
2B6, 2C9, 2C18, 2C19, 2D6, 2E1, and 2J2, and CYP1A1, 2A6, 3A4, 3A5, 1B1,
2B6, 2C8, 2C9, 2C18, 2C19, 2D6, and 2E1, respectively. Purified recombinant
human CYP2C8 protein (cat. no. 456252) and human CYP1A2 protein (cat. no.
456203) were obtained from Corning (Woburn, MA). The other P450 proteins
which were used for cross-reactivity evaluation were also obtained from Corning.
XTreme 200 pooled human liver microsomes (cat. no. H2620) were obtained
from XenoTech (Kansas City, KS).
Protein molecular weight markers were obtained from Life Technologies (cat.
no. LC5602; Carlsbad, CA), and dual color standards were obtained from Bio-
Rad (cat. no. 161-0374; Richmond, CA). Novex 4–12% Tris-Glycine mini gels
were purchased from Life Technologies (cat. no. EC60385BOX). SuperSignal
Western Blot enhancer was purchased from Thermo Scientific (cat. no. 46640;
Rockford, IL). Immobilon-P polyvinylidene fluoride transfer membrane was
purchased from Millipore Corporation (cat. no. IPVH07850; Billerica, MA).
Quantitative Western Blot Analysis. CYP2C8 and 1A2 expressions in
human liver microsomal samples (n = 222) were immunochemically measured by
Western blot analysis as described previously (Naraharisetti et al., 2010).
Preliminary studies were performed to determine CYP2C8 and 1A2 expression
across all ages. Based on the preliminary results, the individual hepatic
microsomal samples, either 5 or 10 mg, were separated by SDS-PAGE along
with purified recombinant CYP2C8 and 1A2 as standards (0.005–1 pmol of
CYP2C8, and 0.0002–0.04 pmol of CYP1A2) and then transferred onto
polyvinylidene fluoride membranes. Each membrane was incubated with 5 ml
of antigen pretreatment solution at room temperature for 10 minutes with shaking,
and subsequently incubated with a mixture of anti-CYP2C8 (1:500 dilution) or
anti-CYP1A2 (1:500 dilution) antibody containing primary antibody diluent at
4C overnight. Subsequently, each membrane was rinsed with Tris-buffered
saline containing 0.1% Tween-20, and then incubated with the corresponding
secondary antibodies (1:5000 dilution) for 1 hour at room temperature. Blots were
scanned using an Odyssey Infrared Imaging system (LI-COR Biosciences). In
each gel, other than unknown samples and one set of standard samples, 2 mg of
commercial pooled human liver microsome (XenoTech) was added as a quality
control sample for interday variation.
The interday coefficients of variation for the microsomal CYP2C8 and
CYP1A2 (n = 19) were 11.3 and 9.2%, respectively. Nonlinear regression
analysis was used to construct a calibration curve to quantify the amount of both
CYP2C8 and CYP1A2 protein in each individual sample based on the integrated
band intensity observedwith the respective purified, recombinant proteins. A one-
site binding regression equation, Y = Bmax*X/(Kd + X), provided in GraphPad
Prism (version 6.0; GraphPad Software, Inc., La Jolla, CA) was used, where X is
the loading amount of each recombinant protein in picomoles, and Y is the band
density integrated using Image Studio Lite software (version 4.0; LI-COR
Biosciences). A value of r2 $ 0.99 was accepted as evidence of good fit for the
standard curve derived from known amounts of either CYP2C8 (0.005–1 pmol) or
1A2 (0.0002–0.04 pmol) (Supplemental Table S1).
Statistical Analysis. Scatter plots of CYP2C8- and CYP1A2-specific content
as a function of age were used to examine overall trends. Classification and
regression tree analysis (R, version 3.1.1, R Foundation for Statistical Computing,
Vienna, Austria) was used to evaluate differences inCYP2C8- andCYP1A2-specific
TABLE 1
Demographics of tissue sample donors
Variable Median Range N % of Total
Age at death
All samples (PCA, weeks) 48.00 8.14–962.29 222 100
Fetal samples only (PCA, weeks) 20.00 8.14–41.00 59 27
Postnatal samples only (months) 3.67 0.033–215.20 163 73
Postmortem interval (hours) 17 1–41 222 –
Sex
Male – – 136 61
Female – – 76 34
Unknown – – 10 5
Ethnicity – –
Northern European – – 92 41
African American – – 84 38
Hispanic – – 19 9
Asian – – 2 1
Native American – – 1 0.5
Biracial – – 1 0.5
Unknown – – 23 10
PCA, postconceptual age; —, not available.
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content among different age groups. Kruskal-Wallis nonparametric tests were used
for statistical comparisons between age groups followed by adjustment for multiple
comparisons using Dunn’s post hoc test (GraphPad Prism, version 7.01). Other
variables were also evaluated using nonparametric testing (GraphPad Prism version
7.01). Linear regression was used to examine relationships between continuous
variables (R, version 3.1.1), and the strength of r2 was considered as highly relevant
(i.e., proximity to 1) in addition to the p value. Stepwise regression testing
(multivariate analysis) was used to evaluate factors potentially contributing to
variation in enzyme protein expression (R, version 3.1.1). A p value less than 0.05
was considered statistically significant. All statistical tests were two-sided.
Results
Western Blot Analysis of Human Hepatic CYP2C8 and
CYP1A2. Western blot analyses revealed a major immunoreactive
band at 56 kDa corresponding to CYP2C8, whereas for CYP1A2, a
single, major immunoreactive band was detected at 58 kDa. Represen-
tative Western blots are shown in Fig. 1, A and B. The upper band in
parallel with CYP2C8 shown in tested human liver microsomal samples
(Fig. 1A) was suspected to be CYP2C9 due to relative cross-reactivity of
the CYP2C8 polyclonal antibodywith CYP2C9 (Supplemental Fig. S1).
However, this signal did not affect the quantitation of CYP2C8, because
CYP2C8 was electrophoretically well separated from the suspected
CYP2C9 band under the current experimental conditions. Anti-
CYP1A2 antibody was specific to CYP1A2 and did not cross-react
with any other recombinant P450 proteins tested in the current study
(Supplemental Fig. S2). No cross-reactivity between the anti-CYP2C8
antibody and CYP1A2 protein or between the anti-CYP1A2 antibody
and CYP2C8 protein was observed (data not shown).
Ontogeny and Interindividual Variation in CYP2C8. Human
CYP2C8 was detectable in the majority of postnatal samples (142 out of
163 samples).With outliers included, defined as having specific contents
outside 1.5 times the 25th to 75th percentiles, the median of microsomal
CYP2C8 was 12.62 pmol/mg microsomal protein (minimum: 0.148,
maximum: 77.98 pmol/mg microsomal protein); however, only consid-
ering the 5th to 95th percentile range, the overall distribution of CYP2C8
content for the entire sample varied about 80-fold. The fetal and early
infancy developmental expression patterns for CYP2C8 are presented in
Fig. 2, A and B, respectively. With the exception of three outliers,
CYP2C8 was either not expressed or expressed at very low levels (,5
pmol/mg microsomal protein) during the human fetal period (n = 60).
However, CYP2C8 was readily detected in most postnatal samples, with
expression occurring as early as the first day of life in some, but not all
microsomal samples (Fig. 2B). No subjects older than 91 days had
nondetectable CYP2C8 expression (Fig. 2B).
Classification tree analysis and confirmatory Kruskal-Wallis testing
of all prenatal and postnatal samples revealed that microsomal CYP2C8
content was significantly lower among the prenatal samples combined
with samples from young infants (,35 days of age) compared with the
older age group (Fig. 3A). This age differential appeared to be driven by
the onset of CYP2C8 expression after birth and progressive increase at
35 days of age (Fig. 3A). CYP2C8 protein levels in the age range of
8 weeks gestation to 35 days postnatal were less than 1% of those in the
age range of 11–18 years. A second node at 11 years was identified by
the initial tree analysis, but it was not statistically significant (p = 0.15)
when considered in conjunction with the 35-day cut point (Fig. 3, A and
B). Thus, samples from fetuses and individuals less than 35 days old
postnatally (n = 100, median [interquartile range (IQR)] = 0.00 [0.00–
0.87] pmol/mg microsomal protein) were significantly lower than those
from postnatal individuals between 35 days and 11 years old [n = 104,
median (IQR) = 12.76 (7.48–22.72) pmol/mg microsomal protein] (p ,
0.0001; Kruskal-Wallis test, Fig. 4); however, the microsomal CYP2C8
expression among individuals in the later age group was not statistically
different from that in the group greater than 11 years of age [n= 18,median
(IQR) = 20.33 (14.78–39.83) pmol/mg microsomal protein; Fig. 4).
Ontogeny and Interindividual Variation in CYP1A2. Human
CYP1A2 was also immunodetectable in the majority of postnatal
samples (101 out of 163). With outliers included as defined previously,
the median of microsomal CYP1A2 was 0.316 pmol/mg microsomal
protein (minimum: 0.00467, maximum: 15.54 pmol/mg microsomal
protein), whereas CYP1A2 content ranged from 0.00772 to 5.497
pmol/mg microsomal protein without considering outliers. Similar to
human CYP2C8, CYP1A2 expression was essentially absent during the
gestational period (Fig. 5A). After birth, CYP1A2 expression levels
were not readily observed in the majority of samples as seen in fetal
samples, indicating that birth may not impact CYP1A2 expression
content. In addition, high interindividual variability was observed
among samples from postnatal individuals ages 0 to 1 year (Fig. 5B).
Classification tree analysis and confirmatory Kruskal-Wallis testing
revealed that microsomal CYP1A2 content was significantly lower in
fetuses and individuals less than 15 months of age [n = 167, median
(IQR) = 0.017 (0.00–0.206) pmol/mg microsomal protein] compared
with older age groups [n = 55, median (IQR) = 2.354 (0.815–4.587)
pmol/mg microsomal protein] (p , 0.0001; Mann-Whitney test, Figs.
6 and 7). This age differential appears to be attributable to the delayed
expression onset in the young, as well as increased CYP1A2 expression
among older individuals.
Factors Affecting Developmental Expression of CYP2C8 and
CYP1A2. Human CYP2C8-specific content was present at significantly
higher levels than CYP1A2-specific content among all samples during
the gestational period and postnatal development (paired t test, p ,
0.0001). There was a positive correlation between values of CYP2C8
and CYP1A2 protein content among both pre- and postnatal age groups
(linear regression, r2 = 0.55 and r2 = 0.34, respectively; p, 0.0001, each
comparison), consistent with the findings from a recent meta-analysis
study (Achour et al., 2014). Both CYP2C8 and CYP1A2 contents in pre-
and postnatal samples were related to age (stepwise linear regression,
r2 = 0.15 and r2 = 0.26, respectively; p, 0.0001). Gender was not related
to either CYP2C8-specific [median (IQR) pmol/mg microsomal protein,
male (n = 136): 5.73 (0.00–18.30), female (n = 76): 6.51 (0.00–18.38),
Mann-Whitney U, p . 0.05] or CYP1A2-specific content [median
(IQR) pmol/mg microsomal protein, male: 0.13 (0.00–1.02), female:
0.09 (0.01–1.52), Mann-Whitney U, p . 0.05]. When age was
considered simultaneously, the influence of gender on either CYP2C8
or CYP1A2 enzyme content continued to be nonsignificant (p. 0.05).
Of note, with age considered simultaneously, race/ethnicity group was no
longer significantly associated with CYP2C8 or CYP1A2 expression.
Fig. 1. Representative Western blots of CYP2C8 and 1A2 in human liver
microsomal samples. (A) Lanes 1–6, purified recombinant CYP2C8 standards (1,
0.4, 0.13, 0.04, 0.015, 0.005 pmol); lanes 7–12, tested human liver microsomal
samples (lower bands, CYP2C8 5 or 10 mg each); lane 13, commercial human
pooled liver microsomal protein as quality control sample (lower band, 2 mg). (B)
Lanes 1–6, purified recombinant CYP1A2 standards (0.04, 0.016, 0.0053, 0.0018,
0.0006, 0.0002 pmol); lanes 7–12, tested human liver microsomal samples (5 or
10 mg each); lane 13, commercial human pooled liver microsomal protein as quality
control sample (2 mg).
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There was no correlation between the postmortem interval (time between
death and freezing of liver samples) and the CYP1A2 expression levels
(linear regression, r2 = 0.017; p . 0.05), whereas there was a positive,
although minor, relationship between the postmortem interval and the
amount of CYP2C8 (linear regression, r2 = 0.049; p , 0.01). Age was
still significantly associated with both CYP2C8 and 1A2 protein
expression levels after adjustment for postmortem interval. With all
factors considered simultaneously, including age, gender, race/ethnic
group, and postmortem interval, only age remained significantly
associated with human hepatic microsomal CYP2C8 and CYP1A2
content (stepwise linear regression, p , 0.001).
Correlations between CYP2C Family and CYP3C4 Protein
Content. Considering some previously reported regulatory mechanisms
shared between human cytochrome P450 enzymes (Honkakoski and
Negishi, 2000), CYP2C8 protein levels were compared with the
previously reported data for CYP2C9, 2C19, and CYP3A4 protein
content determined with similar methods using the same tissue samples
(Stevens et al., 2003; Koukouritaki et al., 2004). In contrast to CYP2C8,
microsomal CYP2C9 and CYP2C19 are readily detected in fetal and
early-life hepatic samples (Fig. 8). Overall, microsomal CYP2C8 protein
expression levels were modestly correlated with those of CYP2C9
(linear regression, r2 = 0.193, p , 0.001), CYP2C19 (r2 = 0.321, p ,
0.001), and CYP3A4 (r2 = 0.304, p, 0.001), suggesting that CYP2C8
may share some developmental regulatory mechanisms with these other
cytochrome P450s.
Discussion
Age-dependent maturation of xenobiotic-metabolizing enzymes can
profoundly impact chemical kinetics in the developing body. In the past
several years, the growing knowledge of enzyme ontogeny has
contributed greatly to improving our qualitative and quantitative
Fig. 2. (A) Human CYP2C8 protein content and age among
microsomal liver fetal samples (n = 60). PCA, postconceptual
age. (B) Human CYP2C8 and age among microsomal liver
samples from the postnatal subjects less than 1 year of age (n =
103). The added solid vertical line represents the 35-day time
point selected by classification tree analysis and confirmed by
statistical testing as appropriate age stratification.
Fig. 3. (A) Age and human CYP2C8 content among
microsomal liver samples from the subset of subjects from
birth to 18 years (n = 162). The added vertical lines represent
the two nodes selected by classification tree analysis indicative
of appropriate age stratification: 35 days (solid line) and
11 years (dotted line). The 35-day age classification (solid line)
was confirmed by Kruskal-Wallis statistical testing followed by
adjustment for multiple comparison using Dunn’s post hoc test,
whereas the 11-year age grouping (indicated by a dotted line)
was not. (B) The relationship between human CYP2C8 content
and age among postmortem microsomal liver samples from
222 human subjects from fetus to 18 years after birth. The
vertical lines represent the two “cut points,” age 35 days and
11 years (from right to left), selected by classification regression
tree analysis as indicative of appropriate age groupings. PCA,
postconceptual age.
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understanding of age-related differences in chemical sensitivity or drug
efficacy/adversity. Such evaluation is possible when enzyme ontogeny
data are used in combination with computational modeling tools, such
as physiologically based pharmacokinetic (PBPK) modeling, which
provides an estimate of the target tissue concentration under given
exposure conditions based on in vitro–based information (Clewell et al.,
2004; Jiang et al., 2013). A major challenge in early-life PBPK
modeling, however, is the difficulty in obtaining extensive biochemical
data, especially metabolic data, for pediatric populations. To overcome
this challenge, a bottom-up process called IVIVE has been increasingly
used to support parameterization of the PBPK models (Clewell et al.,
2004; Johnson et al., 2006; Rostami-Hodjegan and Tucker, 2007; Yoon
et al., 2012). Among the available choices of in vitro assay systems for
age-appropriate metabolism parameters, human recombinant enzymes
have several advantages compared to cell-based or tissue-derived
materials. Fewer sample-quality uncertainties are expected in the
estimated in vivo metabolic constants derived by combining recombi-
nant enzyme activity with enzyme content data compared to those
extrapolated from the data obtained from subcellular fractions or primary
hepatocytes collected from age-specific tissue samples. In addition,
human metabolic variability can be addressed based on observed
variation in enzyme abundance instead of using a large number of
individual donors or volunteers to assess activity. A substantial amount
of data have been collected, resulting in a database describing the
ontogeny of the majority of the key xenobiotic-metabolizing enzymes in
humans; an extensive review of these data can be found in Hines (2008,
2012).
CYP2C8 and CYP1A2 are major hepatic cytochrome P450s,
comprising about 7% and 4–16% of total microsomal cytochrome
P450 content in the adult human liver (Zanger and Schwab, 2013). Both
enzymes play an important role in carrying out oxidative metabolism of
several therapeutic drugs and environmental chemicals, including
pyrethroids (Godin et al., 2007; Guengerich, 2008; Scollon et al.,
2009). However, there is inadequate knowledge of human CYP2C8 and
CYP1A2 ontogeny. Previously reported studies were limited in sample
size at early ages (Cresteil et al., 1982; Lee et al., 1991; Johnson et al.,
2006; Naraharisetti et al., 2010). This study is the first to determine
human hepatic CYP2C8 and CYP1A2 using a large number of prenatal
and postnatal human liver tissue samples.
Both CYP2C8 and CYP1A2 expression were essentially absent
during the gestational period, consistent with increased postnatal
expression of both enzymes being linked to birth. However, the
developmental expression patterns after birth were different. Significant
Fig. 4. Summary of hepatic microsomal human CYP2C8 developmental expression
pattern. CYP2C8-specific content as a function of age was grouped using classification
tree analysis to minimize differences within while maximizing differences between age
brackets. The resulting data are shown as box and whisker plots in which the horizontal
bar represents median CYP2C8 content, boxes represent the upper and lower quartiles,
and vertical bars represent the 5th to 95th percentiles. Outliers, defined as having
specific contents outside 1.5 times the 25th to 75th percentiles, are shown as open
circles. The youngest age group differed significantly from the other two groups (p ,
0.0001, each comparison, Kruskal-Wallis testing), whereas the middle age group did
not differ from the oldest group (p . 0.05).
Fig. 5. (A) Age and human CYP1A2 among fetal hepatic
microsomal samples (n = 60). PCA, postconceptual age. (B)
Age and human CYP1A2 among microsomal liver samples
from postnatal subjects less than 1 year of age (n = 103).
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CYP2C8 expression was observed in early infant samples with an
approximate 8-fold difference in CYP2C8 levels between individuals
less than 35 days postnatal age and older donors (.35 days to 18 years).
In contrast, CYP1A2 protein expression exhibited no significant change
between the fetal and neonatal periods (;30 days). A progressive
increase (;10-fold) in CYP1A2-specific contents was observed after
15 months postnatal age, indicating a delayed CYP1A2 ontogenesis
consistent with earlier findings based on more limited data sets (Sonnier
and Cresteil, 1998). Early quantification studies using probe substrates
and polyclonal antibodies demonstrated CYP1A2 was either not
expressed or expressed at very low levels in human fetal tissues
(Cresteil et al., 1982; Lee et al., 1991). The study by Sonnier and
Cresteil (1998) supported a delayed CYP1A2 ontogeny by reporting that
CYP1A2 was absent in fetal and neonatal microsomal livers, whereas
samples from 1- to 3-month-old infants (n = 23) attained 10–15% of the
adult values, and samples from 3-month to 1-year-old infants reached
20–25% of adult values. Thus, our findings on CYP1A2 are consistent
with earlier reports.
After the specific age thresholds for significant increases in CYP2C8-
and CYP1A2-specific content, microsomal CYP2C8 and CYP1A2
protein expression did not exhibit additional significant age-related
differences. This suggests that, if any developmental changes in
CYP2C8 and CYP1A2 activity occur after about 35 days and 15 months
postnatal, respectively, such changes would be modest and may depend
on exogenous factors (Hines, 2008, 2012). Naraharisetti et al. (2010)
explored human liver CYP2C8 expression and effects of genotype
(CYP2C8*3 or *4), gender, and age onmRNA and/or protein expression
levels. Interindividual variation in CYP2C8 mRNA and protein
expression in 60 liver tissues from Caucasian donors was not shown
to be affected by genetic variation, age, or gender. Given that their
studies were enriched with adult samples (median: 46 years, range: 7–70
years), the lack of an observable age effect on CYP2C8 protein
expression levels is consistent with our findings. Thus, our results
augment the existing but limited knowledge of humanCYP2C8 and 1A2
ontogeny and will enable more accurate assessment of developmental
changes in the disposition, efficacy, and toxicity of drugs and
environmental chemicals.
The variation observed in the overall distribution of CYP2C8 and
CYP1A2 content as well as the variation within individual age groups
was substantial. Several studies have identified CYP2C8 as highly
polymorphic among various ethnic populations, the most common
alleles being CYP2C8*2 and CYP2C8*3 (Totah and Rettie, 2005).
CYP2C8*2 is expressed most commonly in African Americans with an
allele frequency of 18%, but is very rare in Caucasians and Japanese
Fig. 6. (A) Human CYP1A2 content and age among
microsomal liver samples from the subset of postnatal subjects
from birth to 18 years (n = 162). The added solid vertical line
represents the 15-month time point selected by classification
tree analysis and confirmed by statistical testing as appropriate
age stratification. (B) The relationship between human
CYP1A2 and age in postmortem microsomal liver samples
from 222 human subjects from 8 weeks gestation to 18 years
after birth. The vertical line represents the time point selected
by classification regression tree analysis as indicative of
appropriate age groupings (15 months). PCA, postconceptual
age.
Fig. 7. Summary of microsomal human CYP1A2 developmental expression pattern.
CYP1A2-specific content as a function of age was grouped using classification tree
analysis to minimize differences within while maximizing differences between age
brackets. The resulting statistically significant data are shown as box and whisker
plots in which the horizontal bar represents median CYP1A2 content, boxes
represent the upper and lower quartiles, and vertical bars represent the 5th to 95th
percentiles. Outliers, defined as having specific contents outside 1.5 times the 25th
to 75th percentiles, are shown as open circles. The younger age group differed
significantly from the other age group (p , 0.0001, Mann-Whitney testing).
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(Bahadur et al., 2002). In contrast, CYP2C8*3 is most commonly
expressed in Caucasians, with an allele frequency of 23%, but is quite
rare in African Americans and almost absent in Japanese (Soyama et al.,
2001, 2002). Both CYP2C8*2 and *3 alleles are reported to result in
changes in amino acid sequence, leading to altered enzyme expression
levels and metabolic activity toward therapeutic drugs (e.g., paclitaxel)
and endogenous substrate (e.g., arachidonic acid) in vitro and in vivo
(Soyama et al., 2001, 2002; Bahadur et al., 2002). In contrast, the clinical
relevance of multiple CYP1A2 polymorphisms (e.g., CYP1A2*1 or *6)
is controversial (Jiang et al., 2006). Thus, the presence of CYP2C8
genetic polymorphisms among the liver tissue donors may contribute to
the considerable variability observed in CYP2C8-specific content within
and between age groups. Diet influences normal cytochrome P450–
dependent metabolic maturation processes. For example, using caffeine
and dextromethorphan as probes, respectively, formula-fed infants
displayed increased CYP1A1 andCYP3A4metabolic activity compared
with breast-fed infants (Le Guennec and Billon, 1987; Blake et al.,
2006). CYP2C8 and CYP1A2 protein expression and metabolic activity
have also been shown to be induced by therapeutic drugs and smoking
(Totah and Rettie, 2005; Zanger and Schwab, 2013). These observations
implicate genetic polymorphisms and postnatal exposure to dietary
and/or other inducing/suppressing agents (e.g., rifampin and carbamaz-
epine) as having a significant role in the developmental regulation of
cytochrome P450 expression and functional activity from early infancy
(Blake et al., 2006) and likely explain at least some of the interindividual
differences in CYP2C8 and 1A2 expression observed in the current
study.
Constitutive human CYP1A2 expression only occurs in liver (Zanger
and Schwab, 2013). CYP1A2 expression is also regulated by the aryl
hydrocarbon receptor and by other receptors (Pelkonen and Hakkola,
2008), including the constitutive androstane receptor (CAR), and
pregnane X receptor (PXR). Numerous xenobiotics serve as aryl
hydrocarbon receptor, CAR, and PXR agonistic ligands, and thus, can
induceCYP1A2 transcription (Blake et al., 2006; Pelkonen andHakkola,
2008; Zanger and Schwab, 2013). In contrast, human CYP2C8 is
characterized by extrahepatic expression (Klose et al., 1999) as well as
its abundance in the liver (Zanger and Schwab, 2013) and is considered
the most inducible member of the human CYP2C subfamily (Totah and
Rettie, 2005). Three nuclear receptors, PXR, CAR, and the glucocor-
ticoid receptor, are known to be involved in CYP2C8 induction (Gerbal-
Chaloin et al., 2001; Ferguson et al., 2005). These same nuclear
receptors are also involved in the induction and regulation of other
CYP2C family genes (CYP2C9 and CYP2C19) and CYP3A4 (Gerbal-
Chaloin et al., 2001; Ferguson et al., 2005). Thus, the correlation of
hepatic CYP2C8 with CYP2C9, 2C19, and 3A4 protein levels in the
same individuals may be attributed to shared factors that regulate
hepatic-specific expression during development (Koukouritaki et al.,
2004).
Establishment of an in vitro and in silico–based evaluation strategy in
conjunction with relevant human exposure information is of great
importance to risk and safety assessment of potentially vulnerable
populations and life stages. Our data will fill current data gaps in enzyme
ontogeny information for IVIVE-supported prediction of age-dependent
drug and chemical metabolisms. As an example, IVIVE calculation and
in vivo metabolic clearance for a hypothetical compound X, for which
CYP1A2 is a major enzyme involved in hepatic metabolism, are
described in Supplemental Table S2 and Supplemental Fig. S3,
respectively. The immediate utility of the data from the current study
is to predict age-appropriate metabolism parameters for pyrethroid
PBPK models. However, the value of the ontogeny data for these two
Fig. 8. (A) The relationship between microsomal CYP2C8 and CYP2C9 content (linear regression line: y = 0.292x + 8.432, r2 = 0.193, p , 0.001). (B) The relationship
between microsomal CYP2C8 and CYP2C19 content (linear regression line: y = 0.269x + 4.825, r2 = 0.321, p , 0.001). (C) The relationship between microsomal CYP2C8
and CYP3A4 content (linear regression line: y = 0.414x + 2.947, r2 = 0.304, p , 0.001). Also shown is the line of identity (dotted line).
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enzymes is broader, providing the ability to accurately predict age-
dependent hepatic clearance for a variety of chemicals, thereby in-
creasing our confidence in risk and safety decisions for early human life
stages.
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